Literature DB >> 29194504

MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?

Jérome de Seze1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29194504     DOI： 10.1093/brain/awx292

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  5 in total

1.  Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.

Authors:  Liqin Yang; Haiqing Li; Wei Xia; Chao Quan; Lei Zhou; Daoying Geng; Yuxin Li
Journal:  Eur Radiol       Date:  2019-11-20       Impact factor: 5.315

Review 2.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

3.  P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica : P2R Inhibitors Prevent Autoantibody Injury.

Authors:  Sudhakar Reddy Kalluri; Rajneesh Srivastava; Selin Kenet; Goutam K Tanti; Klaus Dornmair; Jeffrey L Bennett; Thomas Misgeld; Bernhard Hemmer; Matthias T Wyss; Marina Herwerth
Journal:  Neurotherapeutics       Date:  2022-07-12       Impact factor: 6.088

Review 4.  Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.

Authors:  Vyanka Redenbaugh; Eoin P Flanagan
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

5.  A highly specific and sensitive nanoimmunosensor for the diagnosis of neuromyelitis optica spectrum disorders.

Authors:  Ariana de Souza Moraes; Doralina Guimarães Brum; Jéssica Cristiane Magalhães Ierich; Akemi Martins Higa; Amanda Stefanie Jabur Assis; Celina Massumi Miyazaki; Flávio Makoto Shimizu; Luís Antonio Peroni; M Teresa Machini; Amilton Antunes Barreira; Marystela Ferreira; Osvaldo N Oliveira; Fabio Lima Leite
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.